ABT-263 is probably ineffective in treating BCL-XL-addicted cancers with low expression of activator BH3s such as BIM, as well as cancers with BCL-XL overabundance, which prevents the BH3-exposed BAK monomers from undergoing homo-oligomerization (Fig. 7c). This evidence concerns the gene BAK1 and cancer.